This company listing is no longer active
Redwood Pharma Past Earnings Performance
Past criteria checks 0/6
Redwood Pharma has been growing earnings at an average annual rate of 1.1%, while the Pharmaceuticals industry saw earnings growing at 8.6% annually.
Key information
1.1%
Earnings growth rate
36.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | n/a |
| Return on equity | -133.5% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Redwood Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -14 | 12 | 0 |
| 31 Dec 23 | 0 | -14 | 12 | 0 |
| 30 Sep 23 | 0 | -16 | 15 | 0 |
| 30 Jun 23 | 0 | -16 | 16 | 0 |
| 31 Mar 23 | 0 | -15 | 15 | 0 |
| 31 Dec 22 | 0 | -13 | 13 | 0 |
| 30 Sep 22 | 0 | -12 | 12 | 0 |
| 30 Jun 22 | 0 | -15 | 15 | 0 |
| 31 Mar 22 | 0 | -19 | 19 | 0 |
| 31 Dec 21 | 0 | -21 | 20 | 0 |
| 30 Sep 21 | 0 | -22 | 21 | 0 |
| 30 Jun 21 | 0 | -18 | 17 | 0 |
| 31 Mar 21 | 0 | -14 | 14 | 0 |
| 31 Dec 20 | 0 | -15 | 15 | 0 |
| 30 Sep 20 | 0 | -14 | 14 | 0 |
| 30 Jun 20 | 0 | -16 | 16 | 0 |
| 31 Mar 20 | 0 | -17 | 17 | 0 |
| 31 Dec 19 | 0 | -16 | 16 | 0 |
| 30 Sep 19 | 0 | -15 | 15 | 0 |
| 30 Jun 19 | 0 | -14 | 14 | 0 |
| 31 Mar 19 | 0 | -16 | 16 | 0 |
| 31 Dec 18 | 0 | -14 | 14 | 0 |
| 30 Sep 18 | 0 | -16 | 16 | 0 |
| 30 Jun 18 | 0 | -18 | 18 | 0 |
| 31 Mar 18 | 0 | -17 | 17 | 0 |
| 31 Dec 17 | 0 | -19 | 19 | 0 |
| 30 Sep 17 | 0 | -17 | 17 | 0 |
| 30 Jun 17 | 0 | -14 | 14 | 0 |
| 31 Mar 17 | 0 | -11 | 11 | 0 |
| 31 Dec 16 | 0 | -9 | 9 | 0 |
| 30 Sep 16 | 0 | -6 | 6 | 0 |
| 30 Jun 16 | 0 | -4 | 4 | 0 |
| 31 Mar 16 | 0 | -2 | 2 | 0 |
| 31 Dec 15 | 0 | 0 | 0 | 0 |
Quality Earnings: REDW is currently unprofitable.
Growing Profit Margin: REDW is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: REDW is unprofitable, but has reduced losses over the past 5 years at a rate of 1.1% per year.
Accelerating Growth: Unable to compare REDW's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: REDW is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.2%).
Return on Equity
High ROE: REDW has a negative Return on Equity (-133.47%), as it is currently unprofitable.